APA

Hohendorff J., Szopa M., Skupien J., Kapusta M., Zapala B., Platek T., Mrozinska S., Parpan T., Glodzik W., Ludwig-Galezowska A., Kiec-Wilk B., Klupa T. & Malecki M. T. (20180416). A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus. : Endocrine.

Chicago

Hohendorff J, Szopa M, Skupien J, Kapusta M, Zapala B, Platek T, Mrozinska S, Parpan T, Glodzik W, Ludwig-Galezowska A, Kiec-Wilk B, Klupa T and Malecki M T. 20180416. A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus. : Endocrine.

Harvard

Hohendorff J., Szopa M., Skupien J., Kapusta M., Zapala B., Platek T., Mrozinska S., Parpan T., Glodzik W., Ludwig-Galezowska A., Kiec-Wilk B., Klupa T. and Malecki M. T. (20180416). A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus. : Endocrine.

MLA

Hohendorff J, Szopa M, Skupien J, Kapusta M, Zapala B, Platek T, Mrozinska S, Parpan T, Glodzik W, Ludwig-Galezowska A, Kiec-Wilk B, Klupa T and Malecki M T. A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus. : Endocrine. 20180416.